Essential Containment Strategies for Operator Safety and Regulatory Compliance

David O’Connell, Director of Scientific Affairs, PCI, explores the containment strategies necessary for operator safety, environmental protection, drug product quality and regulatory compliance when handling HPAPIs. Download the article to learn more about the:

Existing inconsistencies around terminology and potency classification
Levels of containment required
Robust measures for all NPIs
Key factors when choosing a CDMO

Read the Article

Your company email address

Please select your industry: (max 1)

Opt In?

Berne Media may store and process my information. For details, see the Privacy Notice.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By clicking submit, you consent to allow PCI to store and process the information submitted to provide you the content requested. They are subject to PCI's Terms and Conditions.

Essential Containment Strategies for Operator Safety and Regulatory Compliance

Read the Article

Opt In?

Explore similar content

Resiliency and innovation - Navigating the current biotech landscape

HIV – Global Clinical Trial Landscape

Incorporating Digital Biomarkers & Endpoints Into Clinical Trials: Key Regulatory Considerations